Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories Limited reports news on its global pharmaceutical business, including APIs, generics, branded generics, biosimilars and OTC medicines. Company updates cover product approvals and launches in regulated markets, such as generic semaglutide in Canada and OTC ophthalmic products in the U.S., as well as biosimilar development, regulatory submissions and strategic partnerships.
Recurring coverage also includes IFRS financial results, segment trends across Global Generics and Pharmaceutical Services and Active Ingredients, and market activity in the USA, India, Russia and CIS countries, China, Brazil and Europe. Related research releases include Aurigene Oncology updates on oncology programs and targeted protein degradation platforms.
Dr. Reddy's (NYSE:RDY) launched its generic Semaglutide Injection in Canada after receiving a Health Canada Notice of Compliance on April 28, 2026. It is among the first generics in Canada and the first such approval in a G7 country.
The once-weekly GLP-1 therapy is indicated for adults with type 2 diabetes to improve glycemic control alongside diet and exercise, supplied as pre-filled subcutaneous pens in 2 mg/pen and 4 mg/pen strengths.
Dr. Reddy's (NYSE:RDY) received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection on April 29, 2026. The authorization covers 2 mg/pen and 4 mg/pen (1.34 mg/mL), making Dr. Reddy's the first company authorized to market generic semaglutide in Canada.
The API is produced in‑house; finished product manufacturing is currently handled by OneSource Specialty Pharma. Canada has about 3.9 million people diagnosed with diabetes, highlighting the market opportunity for GLP‑1 therapies.
Dr. Reddy's (NYSE: RDY) announced USFDA acceptance of its 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to ORENCIA (abatacept).
The BLA was submitted in December 2025 and accepted for review on February 20, 2026. Phase 1 showed pharmacokinetic similarity; the pivotal Phase 3 study is ongoing.
Dr. Reddy's (NYSE:RDY) launched OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. as a first-to-market generic equivalent to Extra-Strength Pataday once-daily relief, following USFDA approval.
The product is indicated for temporary relief of itchy eyes from pollen, ragweed, grass and animal dander, is sold in a 2.5 mL bottle, and expands Dr. Reddy's existing OTC eye-care portfolio that includes 0.2% and 0.1% olopatadine strengths.
The Pataday brand had U.S. sales of approximately $69.9 million for the 52-week period ending December 27, 2025, per NIQ retail data.
Aurigene Oncology (NASDAQ:RDY) reported initial Phase 1 data for AUR112, an oral MALT1 inhibitor, in relapsed/refractory lymphoid malignancies as of Nov 21, 2025 cutoff. In 11 efficacy-evaluable patients across the first two cohorts, the overall response rate was 63.6% (six partial responses, one complete response); intent-to-treat ORR was 58.3%. Safety was described as generally well tolerated: 84.6% experienced TEAEs, with 14 treatment-related events in seven patients, one DLT (Grade 3 neutropenia) and two DLT-equivalent events. Pharmacodynamics showed rapid, sustained IL-2 suppression; drug exposure at 200 mg appears in the efficacious range. Dose-expansion cohorts for select lymphoid malignancies are planned.
Aurigene Oncology (NASDAQ:RDY) will present new preclinical and platform data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct 22–26, 2025.
Highlights include updates from the A-PROX targeted protein degradation platform and poster data on an orally bioavailable SMARCA2-selective degrader (Abstract C025; Oct 25 12:30–4PM ET). The company cites US FDA IND approval for a SMARCA2-selective degrader and US-FDA clearance for first-in-human studies of LAI candidate AUR110.
Coya Therapeutics (NASDAQ:COYA) has received FDA acceptance of its Investigational New Drug (IND) application for COYA 302, a proprietary immunomodulatory biologic combination therapy for treating Amyotrophic Lateral Sclerosis (ALS). The acceptance enables the company to proceed with a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the treatment's efficacy and safety.
The milestone triggers a $4.2 million payment to Coya from its partner Dr. Reddy's Laboratories (DRL). The development represents a significant step in Coya's partnership with DRL to advance potential treatments for ALS patients.
Dr. Reddy's Laboratories (NYSE:RDY) reported Q1 FY26 financial results with revenues of ₹85,452 Mn, showing an 11% year-over-year growth. The company's gross margin stood at 56.9%, down from 60.4% in Q1FY25. Key highlights include:
The Global Generics segment revenue grew 10% YoY to ₹75,620 Mn, while North America revenues declined 11% YoY due to increased price erosion in products like Lenalidomide. European operations saw significant growth of 142% YoY, largely driven by the acquired Nicotine Replacement Therapy portfolio.
Notable developments include expanded partnerships with Alvotech for biosimilar pembrolizumab and Sanofi for BeyfortusTM launch in India. The company maintained strong financial health with ₹73,169 Mn in cash and investments and achieved an improved 'A' rating in CDP's Climate category.
Bio-Thera Solutions and Dr. Reddy's Laboratories have announced an exclusive commercialization agreement for two biosimilar products: BAT2206 (proposed Stelara® biosimilar) and BAT2506 (proposed Simponi® biosimilar). Under the partnership, Bio-Thera will handle development, manufacturing, and supply, while Dr. Reddy's (RDY) will manage regulatory approvals and commercialization in Southeast Asian territories including Cambodia, Indonesia, Malaysia, Philippines, Thailand, and Vietnam.
Additionally, Dr. Reddy's has secured exclusive commercial rights for BAT2206 in Colombia. This marks Bio-Thera's first partnership focused exclusively on Southeast Asia, aiming to expand access to affordable medicines in emerging markets.